P&G bets $3.8bn on Thorne as Gen Z reshapes the supplements category

Procter & Gamble (NYSE: PG) has agreed to acquire premium supplements brand Thorne for $3.8 billion in cash from LVMH-backed private equity firm L Catterton, in the largest wellness-focused transaction the consumer staples group has attempted in years and its clearest strategic signal that self-care spending has become a central portfolio priority. Chief Executive Officer Shailesh Jejurikar first disclosed the price on CNBC’s Squawk on the Street on August 4, before P&G issued a definitive announcement later the same day. The transaction values Thorne at roughly 5.8 times its projected calendar 2026 revenue of $650 million, a multiple that reflects a compound annual growth rate exceeding 30% since L Catterton’s 2023 take-private, but that also reopens a familiar question for the group’s shareholders: whether P&G is once again buying growth at the price cycle top. The central tension is whether Thorne can meaningfully accelerate the Personal Health Care division, which was the weakest volume performer in the just-reported fourth quarter of fiscal 2026, before integration costs and category competition compress the returns implied by the purchase price.

Why does P&G’s biggest wellness bet in years land on a practitioner-channel supplements brand?

Thorne is not a mass-market vitamin brand. Founded in 1984 and led by former Vitamin Shoppe chief executive Colin Watts, the company built its credibility through licensed healthcare practitioners, NSF Certified for Sport status and a scientific-formulation reputation that translated into premium pricing power. Under L Catterton’s ownership, that heritage was progressively repositioned toward younger direct-to-consumer buyers focused on performance, sleep, cognition and energy. The result, according to disclosures Colin Watts made earlier in 2026, is a customer base of roughly 7 million people, approximately 60% of whom are under the age of 40.

For P&G, the strategic fit is not accidental. Chief Executive Officer Shailesh Jejurikar and P&G Health Care Chief Executive Officer Paul Gama have framed the acquisition as a way to strengthen premium wellness positioning within an existing Personal Health Care portfolio that already includes Metamucil, Align Probiotic and New Chapter, alongside Vicks and Oral-B. What P&G lacked, however, was a brand with genuine credibility inside the practitioner community and with performance-oriented Gen Z and millennial consumers, a segment where Metamucil and Vicks carry limited authority. Thorne fills that gap, and it does so with an AI-powered wellness advisor called Taia and a personalisation stack that P&G’s legacy consumer health brands have not built organically.

The category tailwind is real. The United States vitamins, minerals and supplements market reached approximately $125 billion in 2025, according to data cited by AlixPartners, and is projected to grow around 11% by 2027. Consumer preference has shifted from prevention to performance, a change that plays directly to Thorne’s science-backed positioning. The strategic question is whether P&G can protect that positioning inside a group whose distribution muscle rewards scale and shelf economics rather than practitioner endorsement.

How does Thorne’s valuation compare to its 2023 take-private and the current industry M&A pattern?

L Catterton acquired Thorne through a $680 million take-private in 2023, when the company had gone public only in late 2021 at a $525 million valuation and was guiding to roughly $290 million in annual sales. The $3.8 billion sale to P&G therefore implies a return exceeding five times invested capital in under three years, and a headline gain of more than $3 billion. Managing Partner Marc Magliacano and Partner Rajan Shah publicly framed the transaction as vindication of L Catterton’s operational thesis, but the return also underscores how much of Thorne’s value creation was crystallised inside the private equity holding period rather than left on the table for a public-market acquirer.

Compared with recent transactions, the multiple looks demanding but not unprecedented. Unilever agreed in April 2026 to acquire gummy supplements brand Grüns for an undisclosed sum, while Nestlé has opened a strategic review of what it has publicly described as low-growth, low-margin vitamins, minerals and supplements assets. A Financial Times report in June had suggested Thorne could be valued at up to $4 billion, and Reuters reported that consumer health company Haleon was also in the process. Chief Executive Officer Shailesh Jejurikar declined on CNBC to confirm whether P&G had prevailed in a competitive auction, but the pricing sits comfortably at the top end of the pre-auction range that had been circulated.

For P&G, the payment is manageable on a balance-sheet basis. The company ended June 2026 with $9.9 billion in cash and cash equivalents and generated $19.6 billion in operating cash flow during fiscal 2026, with adjusted free cash flow of $15.8 billion. The Thorne cheque is meaningful but does not require the group to compromise its dividend or share-repurchase cadence, both of which returned more than $15 billion to shareholders during the year. The commercial question is different. At $3.8 billion for a brand with roughly $500 million of 2025 revenue and a projected $650 million in 2026, P&G is paying a growth multiple that will only look reasonable if the compound annual growth rate holds inside a much larger corporate parent.

Can P&G’s underperforming Personal Health Care division absorb a premium direct-to-consumer brand?

The timing of the acquisition invites scrutiny of P&G’s own operating trajectory. In the fourth quarter of fiscal 2026, reported on July 29, the group posted net sales of $21.2 billion, up 2% year-on-year but below the consensus estimate of $21.4 billion. Organic sales were flat, and core earnings per share of $1.43 were down 3% year-on-year, though ahead of the Zacks Consensus. For the full year, organic sales grew slightly more than 1% and core earnings per share rose 1% to $6.89. Management guided fiscal 2027 organic sales growth of 1% to 3% and core earnings per share of $6.89 to $7.11, incorporating roughly $1 billion of after-tax cost pressure from raw materials, energy and transportation linked to the Middle East conflict, and an assumed Brent crude price of about $90 per barrel.

Within that mixed picture, the Health Care segment was the weakest performer by volume in the fourth quarter, even as Beauty grew 6% and Fabric & Home Care rose 1% to $7.4 billion. That is the division into which Thorne will land, and it means P&G is not acquiring an accelerant into a business that is otherwise humming. It is acquiring an accelerant into a business that has been dragging on the group’s volume story. If Thorne’s growth reignites the segment, the strategic logic is straightforward. If Thorne is instead slowed by P&G’s operating rhythms, distribution priorities or shelf-economics logic, the group will have paid a premium price for a brand whose growth rate then converges toward the parent’s.

Integration risk is not just organisational. Thorne’s revenue mix has skewed heavily online, with prior industry estimates placing its own website and Amazon at close to 80% of sales, and the brand also remains the fastest-growing on practitioner platform Fullscript. That is a distribution model P&G has historically deployed only in narrow parts of the portfolio. Preserving practitioner credibility while extracting P&G-level distribution leverage will require the parent to resist the temptation to broaden Thorne into mass channels prematurely, a discipline that consumer staples groups have not consistently demonstrated with premium acquisitions.

What does the failed Haleon bid signal about consolidation in premium supplements?

Haleon, the London-listed consumer health spin-off from GSK, was reportedly the underbidder in the Thorne process. Its interest confirms that the arms race for science-backed wellness assets is now a multi-party auction rather than an opportunistic exercise. Haleon has been trying to demonstrate a growth angle that distinguishes it from its heritage over-the-counter portfolio. Losing Thorne removes one obvious pathway and increases pressure on the group to identify a comparable premium wellness platform, either through a smaller acquisition or through internal brand development.

For the broader category, the transaction sets a public reference multiple that other supplement founders, private equity holders and strategic acquirers will now cite. A 5.8-times revenue print on a brand with a genuine practitioner heritage will encourage secondary sellers to test similar valuations, and it will pressure companies such as Nestlé, which is reviewing its vitamins, minerals and supplements portfolio, to consider whether disposals are best executed while strategic appetite remains this strong. Unilever’s Grüns acquisition earlier in the year had already signalled competitive urgency. Thorne confirms it.

The competitive question for P&G is whether Thorne’s practitioner-channel credibility can be transferred into adjacencies such as personalised diagnostics and connected health. Colin Watts publicly said in April that Thorne could be a “billion-dollar brand over the next few years.” If that path is delivered, the deal will read as an early entry into the personalised-wellness layer of the consumer health stack. If it stalls at $650 million to $800 million, it will read as a premium paid at a market peak.

Which milestones will show whether the acquisition is generating operating leverage?

Because the deal is expected to close later in 2026 subject to regulatory approvals and customary closing conditions, the immediate financial impact on P&G’s fiscal 2027 guidance is limited. Investors should watch for three near-term proof points. First, the closing timeline itself, including any regulatory scrutiny of overlap between Thorne and Metamucil, Align Probiotic and New Chapter, and any behavioural or divestment remedies that emerge. Second, P&G’s first commentary on Thorne’s integration inside the Personal Health Care segment, likely at the fiscal first-quarter results in October, which will indicate whether the group intends to preserve Thorne’s direct-to-consumer and practitioner-channel model or embed it more quickly into P&G’s mass-distribution architecture.

Third, evidence of category expansion inside Thorne itself, particularly around the Taia AI wellness advisor, personalised testing and subscription retention. If Thorne’s compound annual growth rate holds above 20% in the first full year under P&G ownership, the acquisition price will look defensible. If growth compresses toward P&G’s 1% to 3% group organic range, the market will reassess. P&G shares traded modestly higher on August 4 following Shailesh Jejurikar’s CNBC interview, though the reaction was measured rather than emphatic, consistent with a strategic acquisition rather than an earnings surprise.

What still needs to be proved before the Thorne deal looks like a winner for Procter & Gamble shareholders?

What has improved for Procter & Gamble is the strategic optionality of its Personal Health Care division. The group now owns a brand with genuine credibility in premium, science-backed wellness, a direct connection to younger consumers and a personalisation platform it would have struggled to build organically. What remains unresolved is the multiple. Paying close to six times revenue on a brand growing at 30% only works if that growth rate holds through the ownership transition and if Thorne opens adjacent revenue lines rather than simply topping up P&G’s existing supplements portfolio.

The next measurable proof point is closing itself, followed by the first full quarter of P&G ownership commentary. The thesis will strengthen if Thorne’s compound annual growth rate holds, if the practitioner channel is preserved and if Personal Health Care’s volume performance improves as a direct consequence. The thesis will weaken if regulatory scrutiny extends the timeline, if integration slows Thorne’s own growth, or if P&G’s mass-distribution instincts erode the very positioning that justified the purchase price. For a group whose fiscal 2027 guidance already assumes $1 billion in after-tax cost headwinds and a Brent price of about $90 per barrel, the margin for execution error on this deal is not generous.

Key takeaways for executives, investors and industry analysts tracking the Procter & Gamble Thorne acquisition

• Procter & Gamble (NYSE: PG) will acquire Thorne for $3.8 billion in cash from L Catterton’s Flagship Fund, with the transaction expected to close later in 2026 subject to regulatory approval and customary closing conditions.
• The purchase price implies approximately 5.8 times Thorne’s projected calendar 2026 revenue of $650 million, and represents a return exceeding five times invested capital for L Catterton in under three years.
• Thorne generated more than $500 million in 2025 revenue and has compounded at more than 30% annually since being taken private in 2023, with about 60% of its 7-million-strong customer base under the age of 40.
• The acquisition strengthens P&G’s Personal Health Care division, which currently includes Metamucil, Align Probiotic, New Chapter, Vicks and Oral-B, and which was the group’s weakest volume performer in the fourth quarter of fiscal 2026.
• P&G ended June 2026 with $9.9 billion in cash and generated $15.8 billion in adjusted free cash flow during fiscal 2026, meaning the transaction does not compromise the group’s dividend or repurchase framework.
• Haleon was the reported underbidder, confirming that competition for science-backed wellness assets has intensified across large consumer health and staples groups.
• Integration risk centres on preserving Thorne’s practitioner-channel credibility, its direct-to-consumer economics and its AI-driven personalisation stack, including the Taia wellness advisor, while embedding the brand inside a mass consumer-staples parent.
• The United States vitamins, minerals and supplements market reached approximately $125 billion in 2025 and is projected to grow around 11% by 2027, according to AlixPartners data, providing a favourable category backdrop.
• Comparable strategic moves include Unilever’s April 2026 agreement to acquire Grüns and Nestlé’s ongoing strategic review of its vitamins, minerals and supplements assets, both consistent with further consolidation.
• The next measurable proof points for shareholders are the closing timeline, P&G’s first integration commentary at the fiscal first-quarter results, and Thorne’s growth trajectory during its first full year inside the group.